Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Novo Nordisk stock gains 1.12 percent ahead of November 4 results

Analyst downgrade Share buyback AI-generated analysis

πŸ“ˆ Novo Nordisk stock gained 1.12 percent to EUR 34.41 ahead of its first nine-month results scheduled for November 4, 2026.

πŸ“‰ BMO Capital lowered its price target from USD 47.00 to USD 40.00 while maintaining a Market Perform rating due to lower outlook levels.

πŸ’° The company repurchased 23.09 million B shares by October 9 under a program running through February 1, 2027, totaling DKK 6.76 billion.

πŸ“Š Q2 adjusted sales reached DKK 78.49 billion (up 7%) and operating profit hit DKK 33.39 billion (up 11%), though full-year guidance was cut to 0% to -6%.

πŸ’‰ Analysts suggest Wegovy HD injectable uptake is underappreciated, while growth in the oral pill form factor is already reflected in current expectations.

🎯 Novo Nordisk aims to serve more than 60 million patients by 2030, a target set during its September Capital Markets Day.

πŸ“‰ Treasury shares now stand at 1.20 percent of total share capital following recent buyback transactions totaling DKK 10.56 billion since February.

⚠️ The upcoming earnings report will test if volume growth can offset pricing pressure and the lower target levels set by analysts like BMO Capital.

Bullish Signals
  • Novo Nordisk repurchased 23.09 million B shares for DKK 6.76 billion by October 9, reducing outstanding share count and potentially supporting per-share value.
  • Q2 adjusted sales grew 7% to DKK 78.49 billion and operating profit increased 11% to DKK 33.39 billion at constant exchange rates.
  • Analysts indicate that the uptake of Wegovy HD injectable is currently underappreciated by the market, suggesting potential upside in future performance.
  • The company maintains a clear strategic goal to serve more than 60 million patients by 2030, demonstrating long-term growth commitment.
Risk Factors
  • BMO Capital cut its price target from USD 47.00 to USD 40.00 on October 12, citing lower target levels and noting that pill growth is already priced in.
  • The company lowered its full-year adjusted sales and operating profit outlook to a range of 0% to minus 6% at constant exchange rates.
  • Investors are concerned about whether volume growth can offset ongoing pricing pressure before the November 4 earnings release.
Full Analysis
Novo Nordisk shares rose 1.12 percent to EUR 34.41 ahead of its scheduled earnings release for the first nine months of 2026, expected on November 4. The stock's recent performance reflects investor anticipation regarding volume growth against pricing pressures and lower analyst targets. Market sentiment has shifted negatively following BMO Capital's downgrade of its price target from USD 47.00 to USD 40.00 on October 12. Analysts noted that while the uptake of Wegovy HD injectable is underappreciated, growth in the pill form factor is already priced into expectations. Company financial activity includes a significant share repurchase program where Novo Nordisk bought back 23.09 million B shares by October 9 for DKK 6.76 billion. This brings total purchases since February to 37.85 million shares worth DKK 10.56 billion, with treasury shares now at 1.20 percent of capital. Recent Q2 results showed adjusted sales of DKK 78.49 billion and operating profit of DKK 33.39 billion, both up significantly year-over-year. However, the company has lowered its full-year outlook for adjusted sales and operating profit to a range of 0 percent to minus 6 percent at constant exchange rates. Management reaffirmed its strategic goal to serve more than 60 million patients by 2030 during a September Capital Markets Day. The upcoming November earnings report will be critical in testing whether operational volume growth can successfully offset the reduced pricing environment and lower analyst guidance.